Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509958 | 0.89 | PTGDR2 (0.46) | PTGDR2AKR1B1KDM4EPTGS2ABCB11 | |
| SCHEMBL6394892 | 0.87 | AKR1B1 (0.47) | AKR1B1KDM4EPTGS2POLBMAPT | |
| SCHEMBL509488 | 0.84 | PTGDR2 (0.46) | PTGDR2AKR1B1KDM4EPTGS2ALDH1A1 | |
| SCHEMBL508991 | 0.81 | AKR1B1 (0.47) | AKR1B1KDM4EPTGS2 | |
| SCHEMBL510473 | 0.81 | KDM4E (0.50) | PTGDR2KDM4EPTGS2POLBMAPT | |
| SCHEMBL13527342 | 0.81 | ALDH1A1 (0.48) | KDM4EPTGS2MAPTNPSR1ALDH1A1 | |
| SCHEMBL509515 | 0.80 | KDM4E (0.38) | KDM4EPTGS2POLBMAPTNPSR1 | |
| SCHEMBL21846849 | 0.79 | CYP1A2 (0.33) | MAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL3171352 | 0.79 | MAPT (0.37) | AKR1B1KDM4EPTGS2POLBMAPT | |
| SCHEMBL1357312 | 0.79 | AURKA (0.37) | PTGDR2KDM4EPTGS2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629084-B2 | Iodine-phenyl-substituted cyclic cetoenols | BAYER CROPSCIENCE AG (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20100009850-A1 | Iodine-phenyl-substituted cyclic cetoenols | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009850-A1 | Iodine-phenyl-substituted cyclic cetoenols | KCNE1, KCNH3, KCNH2 | PTGDR2 3064/4885AKR1B1 177/4885KDM4E 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.